{
    "organizations": [],
    "uuid": "9bedc795ded77ffea54f6ac19efeb249ba066177",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-xenon-pharmaceuticals-expects-to-h/brief-xenon-pharmaceuticals-expects-to-have-ongoing-xen1101-phase-1-clinical-trial-completed-by-mid-year-idUSFWN1P30QI",
    "ord_in_thread": 0,
    "title": "BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Xenon Pharmaceuticals Inc:\n* XENON PHARMACEUTICALS OUTLINES KEY MILESTONES FOR 2018 * XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR\n* XENON PHARMACEUTICALS INC - IN SECOND HALF OF THIS YEAR, ANTICIPATE HAVING COMPLETED XEN901 PHASE 1 CLINICAL TRIAL\n* XENON PHARMACEUTICALS INC - ANTICIPATE THAT BOTH XEN1101 AND XEN901 COULD BE IN PHASE 2 DEVELOPMENT BY END OF THIS YEAR\n* XENON PHARMACEUTICALS INC - AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $43.7 MILLION\n* XENON PHARMACEUTICALS INC - BASED ON CURRENT ASSUMPTIONS, XENON ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO MID-2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:43:00.000+02:00",
    "crawled": "2018-01-09T16:50:17.017+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "xenon",
        "pharmaceutical",
        "inc",
        "xenon",
        "pharmaceutical",
        "outline",
        "key",
        "milestone",
        "xenon",
        "pharmaceutical",
        "inc",
        "expect",
        "ongoing",
        "xen1101",
        "phase",
        "clinical",
        "trial",
        "completed",
        "xenon",
        "pharmaceutical",
        "inc",
        "second",
        "half",
        "year",
        "anticipate",
        "completed",
        "xen901",
        "phase",
        "clinical",
        "trial",
        "xenon",
        "pharmaceutical",
        "inc",
        "anticipate",
        "xen1101",
        "xen901",
        "could",
        "phase",
        "development",
        "end",
        "year",
        "xenon",
        "pharmaceutical",
        "inc",
        "december",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "million",
        "xenon",
        "pharmaceutical",
        "inc",
        "based",
        "current",
        "assumption",
        "xenon",
        "anticipates",
        "sufficient",
        "cash",
        "fund",
        "operation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}